HOME >> BIOLOGY >> NEWS
Rethinking new therapies for Crohn's disease at U.Va.

CHARLOTTESVILLE, Va., Nov. 11, 2004 In a Perspective article in the Nov. 11 issue of the New England Journal of Medicine, Dr. Fabio Cominelli, chief of the division of gastroenterology and hepatology at the University of Virginia Health System reports that a dysregulated response by the innate immune system- the body's initial, non-specific response to infection- may have more to do with the development of Crohn's than acquired immunity, currently thought by many to be the most likely suspect.

Patients, physicians and medical researchers need to reconsider traditional hypotheses about the biological processes that underlie Crohn's disease, according to Cominelli, a leading Crohn's expert. More than half a million people in the U.S. suffer from Crohn's, a chronic disease involving inflammation of the intestines.

Cominelli indicates that more cytokines- proteins that coordinate the immune response in inflammation- may be involved in Crohn's than scientists had previously thought. He believes that a growing body of evidence shows that both type 1 and type 2 helper T-cells are likely involved in the early stages of Crohn's disease. The classic paradigm held that cytokines secreted by type 1 T-cells, such as TNF (tumor necrosis factor), interleukin-12 and interferon-g were primarily responsible for Crohn's, while type 2 cytokines were linked to ulcerative colitis, another type of inflammatory bowel disease.

Although the underlying cause of Crohn's remains unclear, Cominelli describes an intriguing hypothesis in which a defective innate immune system may be an important player. This could mean that blocking specific type 1 cytokines in the initial phases of Crohn's "may not be beneficial and could actually aggravate the existing disease process," he writes.

Cominelli emphasizes that there are questions about infliximab, the first biological therapeutic approved to treat Crohn's, which blocks the production of the type 1
'"/>

Contact: Bob Beard
reb8e@virginia.edu
434-982-4490
University of Virginia Health System
11-Nov-2004


Page: 1 2

Related biology news :

1. Rethinking anti-oxidants
2. New asthma gene could lead to new therapies
3. Scientists decode RNA mystery, will help aim drug therapies
4. Genomic signatures identify targeted therapies for lung cancer
5. Existence of muscle-building stem cells points to regenerative therapies for muscular disease
6. Antibody-based therapies effective at controlling malaria
7. Preterm infants with RDS -- surfactant replacement therapies improves neonatal survival
8. UBC discovery may lead to smart therapies for breast, ovarian cancer
9. NDDO and ESMO joined by US National Cancer Institute in conferences on targeted cancer therapies
10. U of MN adult stem cell research shows promise for transplant therapies
11. Boost for new cancer therapies

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... ... July 30, 2020 , ... BioFactura, Inc. ... awarded by the Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of ... optimize, and scale-up a highly efficient mammalian cell culture-based bioprocess suitable to meet ...
(Date:7/18/2020)... ... July 16, 2020 , ... A ... of the Invictus Medical Neoasis™ active noise control device to attenuate typical noises ... the Neoasis™ device attenuated the alarm sounds from patient monitors, ventilators and other ...
(Date:7/10/2020)... ... 2020 , ... Today CJ BIO announced the first in a series of ... taste” phenomenon that is revolutionizing ingredient mixes, nutritional content and flavor profiles across a ... July 13, 2020 at11:00 AM (CDT) during SHIFT20, the virtual edition of the IFT ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... N.J (PRWEB) , ... July 29, 2020 , ... ... company, and Catalent, the leading global provider of advanced delivery technologies, development, and ... today announced that they have entered into a strategic partnership whereby Catalent will ...
(Date:7/22/2020)... (PRWEB) , ... July 22, 2020 , ... Join experts ... John Lorenc, Sr. Manager Regulatory Solutions, in a one hour live webinar ... the regulating body in China for drugs and medical devices. Specifically, for medical devices, ...
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra ... life sciences and food industries, is pleased to announce that Charles Galea has ... Business Development. , Charles is an accomplished and results-driven sales executive with over ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage ... Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson ... product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine at ...
Breaking Biology Technology:
Cached News: